Abstract Library

#4658 The nutritional status worsens over 5 years in patients with gastroenteropancreatic neuroendocrine tumours on treatment with somatostatin analogues

Introduction: Malnutrition is common in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with monthly somatostatin analogues (SSAs). Ideally all malnourished patients are offered nutritional support. However, clinical guidelines and data on the development and progression of malnutrition is lacking.

Conference:

Presenting Author: Clement D

Authors: Soran V, Srirajaskanthan R, Cananea E, Martin W, Minott S,

Keywords: gastroenteropancreatic neuroendocrine tumour, malnutrition, somatostatin analogue,

#4648 Analysis of presentation and outcomes of mixed adenoneuroendocrine carcinoma (MANEC) – A single centre experience

Introduction: Mixed adenoneuroendocrine carcinoma (MANEC) is a rare neoplasm characterised by the coexistence of both adenocarcinoma and neuroendocrine carcinoma components. Due to its rarity, limited data exist regarding its clinical presentation, treatment strategies, and outcomes. This study provides an analysis of MANEC cases from a single centre, providing insights into its clinical features, diagnostic challenges, treatment strategies, and prognosis.

Conference:

Presenting Author: Khosla D

Authors: Khosla D, Kapoor R, Mehta A, Gupta R, Singh H,

Keywords: MANEC, mixed adenoneuroendocrine carcinoma, treatment,

#4572 Steroid dosing to prevent tumour flare reaction with 177Lu-DOTATATE

Introduction: Tumour flare reactions including increased pain and small bowel obstruction (SBO) have been reported in patients with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) receiving 177Lu-DOTATATE. Retrospective reviews report tumour flare reactions in 6 to 40 percent of high-risk patients receiving 177Lu-DOTATATE and report success with using corticosteroid prophylaxis to prevent tumour flare recurrence with subsequent doses of 177Lu-DOTATATE (Strosberg, et al., 2021; Salner, et al., 2020).

Conference:

Presenting Author:

Authors: Cass A, Skotte E, Wheless M, Stockton S, Ramirez R,

Keywords: 177Lu-DOTATATE, corticosteroid prophylaxis, tumour flare,

#4564 Vasculogenic mimicry in neuroendocrine tumour across different primary sites

Introduction: Anti-angiogenesis treatments targeting VEGFRs, including Surufatinib and Cabozantinib, etc. showed better efficacy for pancreatic neuroendocrine tumours (NET) than NET of other primary sites. Recent clinical trial targeting tumour necrosis factor receptor-associated protein-1, leading to inhibition of vasculogenic mimicry (VM) showed contrary results to current VEGFRs-targeted treatments. However, VM of NET across different primary sites are yet to be understood.

Conference:

Presenting Author: Chen L

Authors: Chen L, Liang Y, Huang D, Ji S, Chen J,

Keywords: neuroendocrine tumour, pancreatic, extra-pancreatic, vasculogenic mimicry,

#4514 Liver debulking surgery is benefit to PFS in patients with high tumour burden of neuroendocrine tumour liver metastases

Introduction: Liver debulking surgery has shown its definite effect on prolonging survival in patients with neuroendocrine tumour liver metastases (NETLM). However, the effect of liver debulking surgery on the high burden of NETLM is still not clear.

Conference:

Presenting Author:

Authors: Zhou J, Liang Y, Chen J, Wang L,

Keywords: liver debulking surgery, NETLM,